VERAXA Biotech Advances FDA-Aligned Methods to Reduce Animal Testing in Preclinical Research

VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, has provided an update on its strategy to implement U.S. Food and Drug Administration (FDA)-aligned New Approach Methodologies (NAMs) across its preclinical research and development programs. The company said the approach could accelerate clinical advancement, reduce development costs and timelines, and significantly reduce animal testing. This announcement matters because it signals a potential shift in how preclinical research is conducted, aligning with regulatory trends that favor human-relevant models over traditional animal studies. By embracing NAMs, VERAXA aims to de-risk its pipeline while addressing ethical concerns and improving the predictive validity of its preclinical data.

VERAXA has built a panel of NAMs to characterize and de-risk its pipeline of BiTAC-based T cell engagers, antibody-drug conjugates (ADCs), and bispecific antibody-drug conjugates (bsADCs). The company said its lead BiTAC-TCE and bsADC candidates were also evaluated using an ex vivo panel of 10 low-passage patient-derived xenograft models of non-small cell lung cancer. The panel required about 10 mice in total, compared with an estimated 200 or more for comparable in vivo efficacy studies. Across the panel, the combined BiTAC consistently induced potent T cell-mediated killing, supporting the company's dual-targeting approach and demonstrating how its NAM strategy can reduce animal use and preclinical cycle time without compromising clinical relevance. For investors and the biotech industry, this is significant because it shows that NAMs can generate robust efficacy data with far fewer animals, potentially lowering costs and speeding up timelines. To view the full press release, visit https://ibn.fm/9YRJw.

The implications extend beyond VERAXA. If NAMs prove to be as reliable as traditional animal models, they could become a standard in preclinical development, especially as the FDA encourages their use. This could lead to faster regulatory submissions and more ethical research practices. VERAXA's progress with its BiTAC and bsADC candidates, which are designed to harness the immune system to fight cancer, will be closely watched. The company was founded on scientific breakthroughs at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. BiTAC(R) is a registered trademark of VERAXA Biotech GmbH. The latest news and updates relating to VRXA are available in the company's newsroom at http://ibn.fm/VRXA.

BioMedWire, a specialized communications platform focused on the latest developments in the Biotechnology, Biomedical Sciences, and Life Sciences sectors, is one of 75+ brands within the Dynamic Brand Portfolio at IBN. The platform delivers access to a vast network of wire solutions via InvestorWire to efficiently reach target markets, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement to ensure maximum impact, social media distribution via IBN to millions of followers, and a full array of tailored corporate communications solutions. With broad reach and a seasoned team, BioMedWire serves private and public companies seeking to reach investors, influencers, consumers, journalists, and the general public. For more information, visit https://www.BioMedWire.com. Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer.